Publication | Closed Access

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

Metabolic SyndromeHeterozygous Familial HypercholesterolemiaCardiovascular DiseaseHematologyPharmacologyLong-term TreatmentHyperlipidemiaPharmacotherapyMedicineAtherosclerosisDyslipidemiaHealth Sciences